Some “residual uncertainties” in test results acknowledged. This past week, the U.S. Food and Drug Administration approved Biogen’s new drug, Aduhelm, for treating Alzheimer’s disease, which showed in…
Read MoreSome “residual uncertainties” in test results acknowledged. This past week, the U.S. Food and Drug Administration approved Biogen’s new drug, Aduhelm, for treating Alzheimer’s disease, which showed in…
Read More